#United States #New York #cancer therapy #Oramed Pharmaceuticals #Alpha Tau Medical

Oramed Pharmaceuticals Teams Up with Alpha Tau Medical

Oramed Pharmaceuticals Inc. and Alpha Tau Medical Ltd. have just announced a landmark strategic collaboration that promises to revolutionize cancer treatment. Oramed, a pioneering company in the oral delivery of medications, has made a significant investment of $36.9 million into Alpha Tau, a company known for its innovative approach to cancer therapies using alpha-radiation technology.

This financial backing is not just about capital; it's a crucial component of a strategic partnership aimed at accelerating the development of several late-stage cancer treatments. The collaboration will support clinical trials across four different indications in the United States, bolster manufacturing capabilities, and enhance commercialization efforts.

The cornerstone of this partnership lies in the synergetic benefits of each company's strengths. Oramed brings to the table its oral drug delivery platform, which aims to simplify and make drug administration safer for patients who typically require injections. In contrast, Alpha Tau offers a groundbreaking approach to delivering radiation therapy that targets tumors with remarkable precision.

With this investment, Oramed will not only assist Alpha Tau in its market strategies but also take an active role in its governance. Oramed's CEO, Nadav Kidron, has expressed his enthusiasm, stating, "This strategic alliance represents an exceptional opportunity for Oramed to apply our capital markets and business development expertise to support what is poised to bea groundbreaking medical technology." This sentiment is also shared by Alpha Tau’s CEO, Uzi Sofer, who sees great potential in combining their efforts to enhance the delivery of therapies to patients.

Over the next three years, under a comprehensive agreement, the two companies plan to engage in extensive investor outreach and strategic evaluations. This move aims to bolster Alpha Tau's business as it prepares for rapid expansion, reflecting a pivotal moment for both companies in the evolving landscape of cancer treatments.

Oramed is well-recognized for its Protein Oral Delivery (POD™) technology that protects the drug’s integrity while improving absorption, presenting a significant advantage in comparison to conventional delivery methods. Their headquarters are based in the United States, with additional offices in Israel, highlighting their international reach and commitment to advancing health technologies.

Alpha Tau, established in 2016, focuses on developing therapies specifically for treating solid tumors through its Alpha DaRT® technology. This technology is based on research from Tel Aviv University and represents the forefront of oncology therapeutics, marrying scientific innovation with practical application.

Both companies are aware of the inherent challenges and risks in such collaborations, especially in navigating the complexities of medical technology adoption. Kidron and Sofer's passion for transforming how therapies are delivered sets a strong foundation for their future endeavors.

As Oramed prepares to solidify its commitment through active governance by placing two directors on Alpha Tau’s Board of Directors, the industry watches closely. Analysts are optimistic about the prospects of this partnership, forecasting significant advancements, clinical trial successes, and a further reduction in barriers to access cutting-edge cancer therapies.

In conclusion, the collaboration between Oramed Pharmaceuticals and Alpha Tau Medical showcases a bold step toward innovative healthcare solutions, potentially reshaping how cancer therapies are conceived, developed, and delivered to patients globally.